±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 945  |  »Ø¸´: 3
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴

ǰÊÀ½ñÉú

ľ³æ (СÓÐÃûÆø)


[½»Á÷] ¸÷λÐֵܽãÃðïæ·­Òë·Ö×ÓÉúÎïѧÏà¹ØµÄÎÄÏ×°É£¬Ð»Ð»¹þ£¡

ENTPD5 Expression Correlates with AKT Activation in
Human Cancer Cell Lines and Primary Tumor Samples
PTEN mutation and AKT activation are common features for
human cancer. To check whether what was observed in PTEN
null MEFs is also true for human cancer cells, we screened
a panel of human cancer cell lines for the expression of PTEN,
activated AKT, and ENTPD5. As shown in Figure 7A, AKT activation
was seen in human prostate cancer lines C42 and LNCaP
cells, and in these two cell lines, elevated ENTPD5 expression
was also observed.
We also examined ENTPD5 expression and AKT activation in
primary human tumor samples by staining two adjacent sections
from a formalin-fixed, paraffin-embedded human primary prostate
cancer sample with rabbit monoclonal antibodies against
human ENTPD5 and phosphoAKT, respectively. The specificity
of this anti-ENTPD5 antibody was verified by western blotting
analysis using LNCaP cell lines with or without their ENTPD5
knocked down (Figure S6A). The staining intensity for ENTPD5
in tumor was significantly greater compared with adjacent normal
tissue and was correlated with pAKT staining (Figure 7B). Out of
10 samples from patients between age 57 and 76, only one tumor
sample from a 57-year-old patient and another sample collected
from a patient who had just gone through therapy did not show
strongENTPD5staining, and the same tumors were also negative
for pAKT (Figure S6B2 and Figure S6B10). The remaining eight
samples all showed greater tumor staining of pAKT and ENTPD5
(Figure 7B and Figures S6B3¨CS6B9).
Because microarray data of many tumors are publicly available,
we also analyzed a group of recently publicized microarray
data from human prostate cancer samples (Bermudo et al.,
2008). We found that ENTPD5 is highly expressed in all 20 tumor
samples compared to normal prostate epithelium cells (Figure
S7). In addition, after clustering all gene expression profiles
from prostate tumor microarray data using SOM (self-organization
method), we identified dozens of genes associated with
AKT activation, including Her-3, PI3KCB, Ras, S6 kinase,
CD36, IL8, EGF, osteropontin, and FoxO1, which are significantly
coregulated with ENTPD5 (Figure S7).
ENTPD5 Is Important for Cancer Cell Growth
To verify the functional significance of ENTPD5 expression in
human cancer cells, we generated a cell line from the original
LNCaP cells in which an shRNA against human ENTPD5 could
be induced by Dox. In these cells, knockdown of ENTPD5 by
adding Dox to the culture media also lowered N-glycosylation
(Figure 7C, comparing lanes 7 and 8, 9 and 10, and 11 and 12)
and induced BiP expression (Figure 7C, lanes 8, 10, and 12).
These phenotypes were rescued by the expression of a wildtype
shRNA-resistant ENTPD5 transgene, but not by the active
site mutant ENTPD5 (Figure 7C, lanes 13¨C24). Several growth
factor receptors were also checked in these cell lines after Dox
treatment. As shown in Figure 7D, EGFR and Her2/ErbB-2
were significantly down, and IGFRb was slightly down (Figure 7D,
lanes 1¨C4). They were restored to the normal level by the expression
of shRNA-resistant ENTPD5 transgene (Figure 7D, lanes 5
and 6), but not the active site mutant (Figure 7D, lanes 7 and
8). Consistently, when the cell number was measured after
4 day knockdown of ENTPD5, only about half of LNCaP cells
were there, compared to a control knockdown cell line, and
the defect was rescued by expression of wild-type ENTPD5
transgene, but not active site mutant (Figure 7E).
To test whether knocking down ENTPD5 in LNCaP cells also
has an effect on their growth in vivo, we implanted the LNCaP
cells bearing a Dox-inducible shRNA targeting ENTPD5 in matrigel
in nude mice. As a control, LNCaP cells with a Dox-inducible
shRNA targeting GFP were also implanted. After the xenograft
tumors reached the size of 500 mm3, a cohort of seven mice
were fed with Dox-containing water. The level of ENTPD5 in
these tumors was measured after 6 weeks. Compared with
mice fed with normal water, the ENTPD5 levels in ENTPD5-targeting
shRNA containing tumors from mice fed with Dox-containing
water were significantly lower except in one mouse
(Figure 7F). Whereas ENTPD5-targeting shRNA containing
tumors in mice fed with normal water continued to grow, the
tumors in mice fed with Dox-containing water shrank (Figure 7G).
Amazingly, when these tumor samples were analyzed under
a microscope after fixing and staining with hematoxylin and
eosin, there were very few tumor cells left in the matrigel in
tumors grown in Dox-fed mice, whereas in mice fed with normal
water, the matrigel was filled with tumor cells (Figure 7H). The
GFP shRNA-containing tumors did not respond to Dox treatment
and continued to grow during the period of experiment.

» ²ÂÄãϲ»¶

» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:

²é¿´È«²¿É¢½ðÌù

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

zhengchenx

½û³æ (ÖøÃûдÊÖ)


ǰÊÀ½ñÉú(½ð±Ò+1, ·­ÒëEPI+1): 2010-11-27 11:10:13
·¢Ñ¿ÍÁ¶¹(·­ÒëEPI-1):epi·¢·Å´íÎó 2010-11-30 09:49:18
×£¸£Ò»Ï°É
2Â¥2010-11-25 15:43:40
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

bibiaomian

½ð³æ (ÖøÃûдÊÖ)


ǰÊÀ½ñÉú(½ð±Ò+5, ·­ÒëEPI+1):ÒòΪ±ðÈ˵ÁÓÃÁËÎҵĺţ¬ËùÒÔ²»ÊDZ¾ÈË·¢Ìû£¬Í´³âÕâÖÖÐÐΪ£¬²»Äܰ´ÕÕ·¢ÌûÀ´·¢·Å£¬µ«ÊǼøÓÚbibiaomian µÄÐÁ¿à·­Ò뻹ÊÇ~~~~ 2010-12-03 09:04:26
ENTPD5±í´ïÓëAKTµÄ»î»¯
ÈËÖ×Áöϸ°ûÖêºÍÔ­Ö×ÁöÑù±¾
PTEN»ùÒòÍ»±äºÍAktµÄ»î»¯Êǹ²Í¬µÄÌØÕ÷
ÈËÀà°©Ö¢¡£Òª¼ì²éÊÇ·ñ¹Û²ìÖÐPTEN»ùÒòÊÇʲô
¿ÕMEFsϸ°ûÒ²ÊÇÕæÕýµÄÈËÀ఩֢ϸ°û£¬ÎÒÃÇɸѡ
ÈËÀà°©Ö¢ÖÐPTEN±í´ïµÄϸ°ûϵ£¬
¼¤»îAKTºÍENTPD5¡£Èçͼ7AÌõ£¬AktµÄ»î»¯
±»ÈÏΪÔÚÈËÀàǰÁÐÏÙ°©Ï¸°ûϵC42µ¥ÔªºÍLNCaP
ϸ°û£¬²¢ÔÚÕâÁ½¸öϸ°ûϵ£¬±í´ïÉý¸ßENTPD5
Ò²ÓÐÈË¡£
ÎÒÃÇ»¹Ñо¿ENTPD5ÔÚ±í´ïºÍAktµÄ»î»¯
Ö÷ÒªÓÉÁ½¸öÏàÁڵIJ¿·ÖȾɫÈËÀàÖ×ÁöÑù±¾
´Ó¸£¶ûÂíÁ̶ֹ¨£¬Ê¯À¯°üÂñÈËǰÁÐÏÙ°©
°©Ö¢ÑùÆ·ÓëÍõ¥¿Ë¡¿¹Ìå
ÈËÀàENTPD5ºÍphosphoAKT·Ö±ð¡£ÌØÒìÐÔ
ÕâÖÖ·´ENTPD5¿¹ÌåÃâÒßÓ¡¼£ÑéÖ¤
·ÖÎö»ò²»Ê¹ÓÃǰÁÐÏÙ°©Ï¸°ûLNCaPϸ°ûÖêµÄENTPD5
ײµ¹£¨Í¼ÎïS6A£©¡£È¾É«Ç¿¶ÈΪENTPD5
ÔÚÖ×Áö½ÏÏÔ×ÅÌá¸ßÓëÁÚ½üÕý³£
Ïà¹Ø×éÖ¯£¬²¢ÓëȾɫpAKT£¨Í¼7b£©¡£³öÓÚ
10 57ºÍ76ËêÖ®¼ä£¬Ö»ÓÐÒ»¸öÖ×Áö»¼ÕßµÄÑù±¾
Ñù±¾À´×ÔÒ»Ãû57ËêµÄ²¡ÈË£¬ÁíÒ»¸öÑùÆ·²É¼¯
´ÓË­¸Õ¸Õͨ¹ýÖÎÁƲ¡È˲¢Ã»ÓÐÏÔʾÁË
strongENTPD5staining£¬Í¬ÑùµÄÖ×ÁöÒ²²»Àû
ΪpAKT£¨Í¼S6B2ºÍͼS6B10£©¡£ÆäÓà°Ë
ËùÓÐÑùÆ·¶¼±íÏÖ³ö¸ü´óµÄÖ×ÁöpAKTºÍENTPD5Ⱦɫ
£¨Í¼7BºÍͼS6B3 - S6B9£©¡£
ÓÉÓÚ¶àÖÖÖ×Áö»ùÒòоƬÊý¾ÝµÄ¹«²¼£¬
ÎÒÃÇ»¹·ÖÎöÁË×î½ü¹«²¼Ð¾Æ¬×é
´ÓÈËÀàǰÁÐÏÙ°©Ñù±¾Êý¾Ý£¨BermudoµÈ¡£
2008Ä꣩¡£ÎÒÃÇ·¢ÏÖ£¬ENTPD5¸ß¶È±í´ïÔÚËùÓÐ20¸öÖ×Áö
ÑùÆ·Ïà±È£¬Õý³£Ç°ÁÐÏÙÉÏÆ¤Ï¸°û£¨Í¼
Æß£©¡£´ËÍ⣬ÔÚËùÓлùÒòµÄ±í´ïÆ×¾ÛÀà
ǰÁÐÏÙÖ×Áö»ùÒòоƬÊý¾ÝʹÓÃË÷Ä·£¨×Ô×éÖ¯
·¨£©£¬ÎÒÃÇÈ·¶¨Á˼¸Ê®¸öÏà¹ØµÄ»ùÒò
AKTµÄ»î»¯£¬°üÀ¨ËýµÄ- 3£¬PI3KCB£¬À­Ë¹£¬S6¼¤Ã¸£¬
CD36µÄ£¬IL8£¬±íƤÉú³¤Òò×Ó£¬osteropontinºÍFoxO1»ùÒò£¬ÕâÊÇÏÔ×Å
Эͬµ÷½ÚÓëENTPD5£¨Í¼Æß£©¡£
ENTPD5Êǰ©Ö¢Ï¸°ûÉú³¤µÄÖØÒª
ΪÁËÑéÖ¤ENTPD5±í´ïµÄ¹¦ÄÜÒâÒå
ÈËÀ఩ϸ°ûÖУ¬ÎÒÃDzúÉúÁË´Óԭʼϸ°ûϵ
LNCaPϸ°ûÖУ¬ÊǶÔÈËÀàENTPD5 shRNAÄÜ
°¢Ã¹ËØ¿ÉÓÕµ¼¡£ÔÚÕâЩϸ°ûÖУ¬ÒÔ»÷µ¹ENTPD5
Ôö¼Ó°¢Ã¹ËصÄÅàÑø»ùÒ²½µµÍµÄN -ÌÇ»ù»¯
£¨Í¼7c£¬±È½ÏÓ¾µÀ7ºÍ8£¬9£¬10£¬11ºÍ12£©
ºÍÓÕµ¼BiPµÄ±í´ï£¨Í¼7c£¬Ó¾µÀ8£¬10ºÍ12£©¡£
ÕâЩ±íÐ;ȳöÁËÒ»¸öÒ°Éú±í´ï
shRNAµÄÄÍENTPD5ת»ùÒò£¬µ«²»ÊÇÓÉ»îÔ¾
ÍøÕ¾£¨Í¼7c£¬Ó¾µÀ13-24£©Í»±äENTPD5¡£¶àÖÖÉú³¤
Òò×ÓÊÜÌ廹¼ì²éÁËÔÚÕâЩϸ°ûÖêºó£¬°¢Ã¹ËØ
ÖÎÁÆ¡£Èçͼ7DµÄ£¬EGFRºÍHer2/ErbB-2
¾ùÏÔ×ÅϽµ£¬IGFRbÊÇС·ùϽµ£¨Í¼7DµÄ£¬
Ó¾µÀ1-4£©¡£ËûÃǻָ´µ½Õý³£Ë®Æ½µÄ±í´ï
µÄshRNAÄÍENTPD5ת»ùÒò£¨Í¼7DµÄ£¬´ø5
6£©£¬¶ø²»ÊÇÍ»±äµÄ»îÐÔ²¿Î»£¨Í¼7DµÄ£¬Ó¾µÀ7
8£©¡£Ò»Ö£¬µ±ºó²â¶¨Ï¸°ûÊý
4 ENTPD5Ìì»÷µ¹£¬Ö»ÓдóÔ¼Ò»°ëµÄLNCaPϸ°û
ÔÚÄÇÀ¶ø¿ØÖÆ»÷µ¹Ï¸°ûϵ£¬
ȱÏݱ»¾È³öµÄÒ°ÉúÐÍENTPD5±í´ï
ת»ùÒò£¬µ«²»»îÔ¾µÄÍøÕ¾Í»±ä£¨Í¼7E£©¡£
ΪÁ˲âÊÔÊÇ·ñײµ¹ÔÚLNCaPϸ°ûENTPD5Ò²
ÓÐËüÃÇÔÚÌåÄÚÉú³¤µÄÓ°Ï죬ÎÒÃÇÖ²ÈëǰÁÐÏÙ°©Ï¸°ûLNCaP
ϸ°û»ùµ×ĤһÖá³ÐÃ¹ËØÓÕµ¼µÄshRNA°ÐÏòENTPD5
ÔÚÂãÊóÌåÄÚ¡£×÷Ϊ¶ÔÕÕ£¬LNCaPϸ°ûÓë°¢Ã¹ËØÓÕµ¼
GFPµÄshRNAµÄÄ¿±êÒ²Ö²Èë¡£ÒÆÖ²ºó
Ö×Áö´ïµ½Îå¡ð¡ðÁ¢·½ºÁÃ׵ĴóС£¬ÆßСÊó¶ÓÁÐ
°¢Ã¹ËØËÇιº¬ÓÐË®¡£Ë®Æ½µÄENTPD5
ÕâЩÖ×ÁöµÄ6Öܺó²â¶¨¡£Ïà±È
ÓëÕý³£Ë®Î¹ÑøÀÏÊó£¬ÔÚENTPD5µÄENTPD5ˮƽ¶¨Î»
shRNAµÄº¬Ö×ÁöÓë°¢Ã¹ËØÎ¹Ê³º¬
Ë®³ýÔÚÒ»ÏÔ׎µµÍСÊó
£¨Í¼7Â¥£©¡£¼øÓÚENTPD5¶¨Î»shRNAµÄº¬
Ë®ÓëÕý³£Î¹ÑøÐ¡ÊóÖ×Áö¼ÌÐøÔö³¤£¬
ÔÚСÊóÌåÄÚÖ×ÁöÃ¹ËØËÇιº¬Ë®·Öϵø£¨Í¼7´ú£©¡£
ÁîÈ˾ªÑȵÄÊÇ£¬µ±ÕâЩÖ×ÁöÑù±¾½øÐÐÁË·ÖÎöÏÂ
¹Ì¶¨ºó£¬ÓëËÕľȾɫºÍÏÔ΢¾µ
Êïºì£¬Óм«ÉÙÊýÖ×Áöϸ°ûµÄ»ùµ×ĤÁôÔÚ
Éú³¤ÔÚ°¢Ã¹ËØÎ¹ÑøµÄСÊó£¬ÔÚСÊóÓëÕý³£Î¹Ñø£¬¶øÖ×Áö
Ë®£¬»ùµ×ĤÃÖÂþ×ÅÖ×Áöϸ°û£¨Í¼7Сʱ£©¡£¸Ã
GFPµÄshRNAµÄº¬Ö×ÁöûÓлØÓ¦Ã¹ËØÖÎÁÆ
²¢¼ÌÐøÔö³¤£¬ÔÚʵÑéÆÚ¡£
3Â¥2010-12-03 08:50:53
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ǰÊÀ½ñÉú

ľ³æ (СÓÐÃûÆø)


֮ǰÓÐÈ˵ÁÓÃÁËÎҵĺţ¬¼¸ÌìÖ®¼äÀûÓÃÎҵĺÅ×öÁËһЩÊÂÇé£¬ÌØ´ËÉùÃ÷£¡
4Â¥2010-12-03 08:57:59
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ ǰÊÀ½ñÉú µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ¸´ÊÔµ÷¼Á +5 asdasdassda 2026-04-05 5/250 2026-04-06 09:32 by dongzh2009
[¿¼ÑÐ] 302·ÖÇóµ÷¼Á Ò»Ö¾Ô¸°²»Õ´óѧ085601 +8 zyxÉϰ¶£¡ 2026-04-04 8/400 2026-04-05 23:08 by lbsjt
[¿¼ÑÐ] Çóµ÷¼Á +11 ÐܶþÏëÉϰ¶ 2026-04-04 11/550 2026-04-05 22:21 by ×íÎÌwl
[¿¼ÑÐ] 301Çóµ÷¼Á +3 XYPLR 2026-04-05 4/200 2026-04-05 19:07 by XYPLR
[¿¼ÑÐ] ¸´ÊÔµ÷¼Á +8 ´ºÈÕÀ´ÐÅ- 2026-04-03 8/400 2026-04-05 18:58 by À¶ÔÆË¼Óê
[¿¼ÑÐ] µ÷¼ÁÇóÖú +10 Ïë»»ÊÖ»ú²»Ïë½âÊ 2026-04-02 13/650 2026-04-05 09:41 by sam3303
[¿¼ÑÐ] ¿¼Ñе÷¼Á +6 15615482637 2026-04-04 6/300 2026-04-04 22:43 by yu221
[¿¼ÑÐ] 283·ÖÇóµ÷¼Á +7 СÄô°®Ñ§Ï° 2026-04-03 7/350 2026-04-04 21:51 by hemengdong
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +12 Ò»ÑùYWY 2026-04-02 13/650 2026-04-04 20:49 by À¶ÔÆË¼Óê
[¿¼ÑÐ] һ־Ը˫·Ç085502£¬267·Ö£¬¹ýËļ¶Çóµ÷¼Á +3 ÔÙæҲҪ³Ô·¹°¡ 2026-04-03 3/150 2026-04-04 05:03 by gswylq
[¿¼ÑÐ] 315Çóµ÷¼Á +6 ˳Àí³ÉÕÅ 2026-04-03 8/400 2026-04-03 14:04 by °ÙÁéͯ888
[¿¼ÑÐ] ÊýÒ»Ó¢Ò»285Çóµ÷¼Á +7 AZMK 2026-04-03 9/450 2026-04-03 13:03 by ms629
[¿¼ÑÐ] 330Çóµ÷¼Á +3 °×ÉñÎØºôºô 2026-04-02 3/150 2026-04-03 10:15 by À¶ÔÆË¼Óê
[¿¼ÑÐ] ²ÄÁÏ¿¼Ñе÷¼Á +10 Gs´óÍõ 2026-04-02 10/500 2026-04-03 09:47 by ÒÅÍüÏûʧµÄž™
[¿¼ÑÐ] Ò»Ö¾Ô¸¸´µ©²ÄÁÏ£¬Ó¢Ò»×¨Ë¶£¬×Ü·Ö357µ÷¼Á +4 1050389037 2026-04-02 5/250 2026-04-02 21:40 by dongzh2009
[¿¼ÑÐ] Çóµ÷¼ÁÍÆ¼ö +3 ÄÏɽÄÏ@ 2026-04-01 3/150 2026-04-02 12:09 by xiaoranmu
[¿¼ÑÐ] 279Çóµ÷¼Á +6 ѧ¶øË¼ÙâÖª 2026-04-01 6/300 2026-04-02 09:16 by vgtyfty
[¿¼²©] 26ÄêÉ격 +3 staryer 2026-03-30 4/200 2026-04-01 23:21 by ai4pharm
[¿¼ÑÐ] 11408 321·ÖÇóµ÷¼Á +3 huchun12138 2026-03-30 4/200 2026-04-01 22:48 by guanxin1001
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +11 Ò»ÑùYWY 2026-03-31 11/550 2026-04-01 11:35 by wangjy2002
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û